Skip to main content

Table 2 Study-agent related adverse events

From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Adverse Event

Grade 1

Grade 2

Grade 3–4

Injection Site Pain

10

0

0

Headache

6

0

0

Fatigue

6

1

0

Anorexia

1

1

0

Fever

2

0

0

Nausea

3

2

0

Rash

2

0

0

Infection

0

0

0

Respiratory

1

0

0

Hepatic

2

0

0

Thrombocytopenia

1

0

0

Anemia

1

0

0

Infection

1

0

0